L'intérêt à découvert pour NextCure donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de NextCure. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

NextCure (NASDAQ:NXTC) Stock, Rapport sur les intérêts à découvert

NEXTCURE INC

NextCure

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Barclays analyst Emily Field downgrades Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) from Overweight to Equal-Weight.

News

Downgrades

Analyst Ratings

Barclays Downgrades Novo Nordisk to Equal-Weight

Verisk Analytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) narrows FY2025 Adj EPS guidance from $6.80-$7.10 to $6.80-$7.00 vs $7.04 analyst estimate. Raises FY2025 sales outlook from $3.030 billion-$3.080 billion to $3.090 billion-$3.130 billion vs $3.078 billion estimate.

Guidance

VRSK

Verisk Analytics Narrows FY2025 Adj EPS Guidance from $6.80-$7.10 to $6.80-$7.00 vs $7.04 Est; Raises FY2025 Sales Guidance from $3.030B-$3.080B to $3.090B-$3.130B vs $3.078B Est

Navient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAVI#NASDAQ">NAVI</a>) lowers FY2025 Adj EPS guidance from $1.00-$1.20 to $0.95-$1.05 vs $1.08 analyst estimate..

NAVI

Navient Lowers FY2025 Adj EPS Guidance from $1.00-$1.20 to $0.95-$1.05 vs $1.08 Est

Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) second-quarter report didn&#8217;t sit well with longtime Tesla shareholder Ross Gerber, who pulled no punches in an interview following the release.
&#8220;Yeah, I mean, it&#8217;s garbage,&#8221; the CEO of Gerber Kawasaki Wealth and Investment Management, told <a href="https://www.youtube.com/watch?v=TjzEpljd80I">Yahoo Finance</a>, just after the report was released. &#8220;It&#8217;s sad and depressing to me that this is a business in decline when it should be&#8230; a growing business, and it&#8217;s not.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">"It's garbage, it's sad and depressing to me that this is a business in decline," Gerber Kawasaki Wealth &amp; Investment Management CEO <a href="https://twitter.com/GerberKawasaki?ref_src=twsrc%5Etfw">@GerberKawasaki</a> says about <a href="https://twitter.com/search?q=%24TSLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TSLA</a>. <a href="https://t.co/ONXGSb9Iue">pic.twitter.com/ONXGSb9Iue</a>
&mdash; Yahoo Finance (@YahooFinance) <a href="https://twitter.com/YahooFinance/status/1948127627006685350?ref_src=twsrc%5Etfw">July 23, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul class="wp-block-list">
<li>7,000+ investors have joined Timeplast's mission to eliminate microplastics—now it's your turn to <a href="https://www.benzinga.com/money/timeplast-advertorial">invest in the future of sustainable plastic before time runs out.</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
<h2 class="wp-block-heading">Revenue Down, Sentiment Lower</h2>
On July 23, Tesla <a href="https://www.tesla.com/sites/default/files/downloads/TSLA-Q2-2025-Update.pdf">reported</a> $22.5 billion in revenue for the second quarter, <a href="https://www.benzinga.com/markets/earnings/25/07/46587882/tesla-q2-earnings-highlights-revenue-and-earnings-fall-short-new-models-still-set-for-2025-2026">down 12% from a year earlier</a>, short of Wall Street&#8217;s $22.8 billion estimate. Automotive revenue fell even more sharply, dropping 16% year-over-year to $16.66 billion. Per-share earnings were 40 cents, missing the expected 42 cents. Operating income dropped 42% to $923 million, with operating margins falling to 4.1%.
Gerber criticized Tesla's shrinking cash flow, noting that the company is now essentially break-even without regulatory credits. &#8220;The regulatory credits are going down every quarter and they&#8217;re <a href="https://www.benzinga.com/markets/earnings/25/07/46594381/elon-musk-says-tesla-could-face-a-few-rough-quarters-as-ev-incentives-expire-and-trump-tariff-pressures-mount">going to be gone soon</a>,&#8221; he said. &#8220;And the prices are going up on the vehicles soon. So I&#8217;m just like, man, you know, this sucks.&#8221;
Deliveries also fell to 384,122 vehicles, down from 443,956 in the same period last year. Production held steady at just over 410,000 units.
Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a>
<h2 class="wp-block-heading">High-End Sales Collapse And Brand Troubles</h2>
Gerber pointed to a 54% drop in sales of Tesla&#8217;s high-end vehicles, including the Model S, Model X, and Cybertruck. While he said he <a href="https://www.benzinga.com/markets/tech/25/07/46259057/ross-gerber-gary-black-weigh-in-on-tesla-cybertrucks-poor-sales-a-very-sad-result">likes the Cybertruck personally</a>, he criticized Tesla for not doing enough to market it.
He also warned that no matter how many new models Tesla produces, it won't matter if <a href="https://www.benzinga.com/markets/tech/25/07/46594012/teslas-new-model-y-trim-wont-expand-market-offers-zero-incremental-volume-says-gary-black">customers aren&#8217;t interested</a>. &#8220;It doesn&#8217;t matter how many products you come up with if people don&#8217;t want to buy them,&#8221; Gerber said. &#8220;They just don&#8217;t seem to want to address that issue.&#8221;
While Tesla touted early production of a <a href="https://www.benzinga.com/markets/tech/25/07/46212911/amid-declining-sales-elon-musks-tesla-confirms-new-affordable-models-will-be-introduced-this-year">more affordable model</a> set for volume release late this year, Gerber was skeptical. He acknowledged the need for a lower-cost vehicle but doubted that a <a href="https://www.benzinga.com/markets/asia/25/04/45032179/tesla-reportedly-developing-a-cheaper-model-y-e80-variant-with-fewer-features-in-china">smaller Model Y</a> would move the needle. &#8220;You&#8217;re going to lose—you&#8217;re going to cannibalize more of your business,&#8221; he warned.
<h2 class="wp-block-heading">Musk&#8217;s Influence And Image Problem</h2>
The Tesla bull didn't shy away from addressing what he sees as a core issue: CEO Elon Musk's behavior. &#8220;Even if they came out with a golden car that flew, people wouldn&#8217;t buy it because it&#8217;s Elon Musk&#8217;s car,&#8221; Gerber said.
See Also: How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.
He argued that Musk&#8217;s political commentary and <a href="https://www.benzinga.com/news/politics/25/07/46215609/elon-musk-regrets-cpac-chainsaw-stunt-it-lacked-empathy">public actions</a> have alienated potential buyers. &#8220;Elon&#8217;s political, not just opinions, but his actual behavior in public is just super inappropriate and turns off basically everybody now,&#8221; he said. &#8220;Until he wants to address that, I still think it&#8217;s going to be hard for Tesla to grow.&#8221;
Though Gerber supports <a href="https://www.benzinga.com/personal-finance/management/25/07/46510590/elon-musk-returns-to-intense-work-schedule-back-to-working-7-days-a-week-and-sleeping-in-the-office">Musk returning to a more active CEO role</a>—&#8221;The CEO of the company should actually work at the company&#8221;—he said that won't fix the brand image alone. &#8220;Probably the best thing he could do is work at Tesla and never tweet again,&#8221; he added.
Gerber also isn&#8217;t convinced that robotaxis are a game-changer. &#8220;What is so exciting about a business that&#8217;s been around for a long time?&#8221; he said. &#8220;I get in a Waymo. It takes me from A to B. Costs me 20 bucks. Big deal.&#8221;
He also expects Tesla to eventually acquire xAI, Musk&#8217;s AI startup, which would give Musk more control of Tesla. &#8220;Sadly, I think Tesla&#8217;s shareholders are going to vastly overpay for xAI,&#8221; he said. &#8220;They need the cash out of Tesla&#8217;s balance sheet for xAI to grow.&#8221;
Despite all his concerns, Gerber said he&#8217;s still long Tesla and isn't betting against Musk. But he&#8217;s clear-eyed about what needs to change: &#8220;Maybe in a year things get better. But if he doesn&#8217;t change the way he&#8217;s acting, I don&#8217;t see how anything gets better.&#8221;
Read Next: These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a>
Image: Imagn Images

TSLA

Ross Gerber Calls Tesla's Q2 Report 'Garbage.' He Says It's 'Sad And Depressing' To See The Company Is In Decline

Morgan Stanley analyst James Faucette maintains Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) with a Overweight and raises the price target from $386 to $402.

Price Target

Morgan Stanley Maintains Overweight on Visa, Raises Price Target to $402

Redwood Trust Upsizes Common Stock Repurchase Authorization To $150M, Reinforcing Confidence In Strategic Growth And Shareholder Value

ProPetro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PUMP#NYSE">PUMP</a>) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $0.05 by 240 percent. This is a 133.33 percent decrease over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $326.151 million which missed the analyst consensus estimate of $328.859 million by 0.82 percent. This is a 8.65 percent decrease over sales of $357.021 million the same period last year.

Earnings

Earnings Misses

PUMP

ProPetro Holding Q2 EPS $(0.07) Misses $0.05 Estimate, Sales $326.151M Miss $328.859M Estimate

KORE

KORE And TD SYNNEX Form Strategic Alliance To Streamline IoT Connectivity Access And Deployment Via OmniSIM US Offering

JP Morgan analyst Brian Ossenbeck downgrades Norfolk Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) from Overweight to Neutral and raises the price target from $282 to $288.

JP Morgan Downgrades Norfolk Southern to Neutral, Raises Price Target to $288

Due to continued macroeconomic uncertainty related to the impact of new tariffs on goods imported into the United States, the company is not providing 2025 financial guidance at this time.

SHOO

Steven Madden Withholds 2025 Outlook Citing Uncertainty From New US Tariffs

Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 176.47 percent decrease over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $28.22 million which beat the analyst consensus estimate of $27.70 million by 1.87 percent. This is a 32.69 percent decrease over sales of $41.92 million the same period last year.

Earnings Beats

ANIK

Anika Therapeutics Q2 Adj. EPS $(0.13) Beats $(0.17) Estimate, Sales $28.22M Beat $27.70M Estimate

Verisk Analytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) reported quarterly earnings of $1.88 per share which beat the analyst consensus estimate of $1.77 by 5.98 percent. This is a 8.05 percent increase over earnings of $1.74 per share from the same period last year. The company reported quarterly sales of $772.600 million which beat the analyst consensus estimate of $768.320 million by 0.56 percent. This is a 7.75 percent increase over sales of $717.000 million the same period last year.

Verisk Analytics Q2 Adj. EPS $1.88 Beats $1.77 Estimate, Sales $772.600M Beat $768.320M Estimate

Taiwan-based United Microelectronics Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMC#NYSE">UMC</a>), a prominent global semiconductor foundry, saw its<a target="_blank" href="https://www.benzinga.com/topic/semiconductor" rel="noreferrer noopener"> stock price fall</a> on Wednesday after reporting fiscal second-quarter results that largely disappointed market expectations.
For the quarter, the company reported revenue of $2.01 billion (58.76 billion New Taiwanese dollars), marking a modest 3.4% increase year-on-year. However, this figure missed the analyst <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus estimate of $2.05 billion</a>.
On a sequential basis, <a target="_blank" href="https://www.umc.com/en/Download/quarterly_results/QuarterlyResultsDetail/2025/2025Q2" rel="noreferrer noopener">revenue</a> saw a slight uptick of 1.6%. Earnings per American Depositary Share (ADS) came in at 12 cents, also missing the analyst consensus of 14 cents.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46687078/booming-taiwan-chip-industry-faces-critical-worker-shortage" rel="noreferrer noopener">Booming Taiwan Chip Industry Faces Critical Worker Shortage</a>
Despite the overall miss, the company showcased progress in its advanced process nodes. Revenue derived from 22nm and 28nm technologies accounted for a record 40% of wafer revenue, a significant increase from 33% reported a year ago.
The contribution from 40nm technology experienced a marginal sequential decline, even as its share of total sales modestly increased to 15% from 12% in the prior year. Capacity utilization showed improvement, rising to 76% from 68% year-over-year.
However, the gross margin contracted to 28.7% from 35.2% in the same period last year. Capital expenditures for the quarter totaled $273 million.
United Microelectronics Co-President Jason Wang provided a detailed overview of the quarter&#8217;s performance and strategic initiatives. He noted that the company&#8217;s utilization rate improved to 76% in the second quarter, driven by a 6.2% quarter-over-quarter increase in wafer shipments.
This growth was primarily fueled by robust demand in the communications sector for imaging signal processors, NAND controllers, WiFi, and LCD controllers.
Wang acknowledged that while overall utilization increased and the 22/28nm portfolio expanded, an unfavorable New Taiwanese dollar exchange rate impacted profitability, reducing the gross margin by nearly three percentage points to 28.7%.
He emphasized the continued sequential growth of revenue from the 22/28nm portfolio, which reached a record 40% of total sales in both percentage and absolute dollar terms.
Wang asserted that &#8220;the company&#8217;s industry-leading 22/28nm solutions gained further customer adoption,&#8221; and the company anticipates gaining market share in wireless communications in the upcoming quarters.
Reaffirming confidence in the long-term strength and differentiation of the 22/28nm node, he highlighted that the new Phase 3 facility at Singapore&#8217;s Fab 12i, slated for production in 2026, will play a crucial role in supporting customers seeking diversified manufacturing options for enhanced supply chain resilience.
Looking ahead to the third quarter, Wang cautioned that while the company anticipates a modest increase in wafer shipments, adverse foreign exchange trends are expected to reduce revenue when denominated in New Taiwanese dollars. The company remains vigilant in monitoring short-term uncertainties, including potential shifts in U.S. tariff policies.
<h2 class="wp-block-heading">Outlook</h2>
For the third quarter, United Microelectronics <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">projects</a> wafer shipments to increase by a low-single-digit percentage, with the average selling price (ASP) expected to remain flat. The company anticipates a quarterly gross margin of approximately 28.7% and capacity utilization in the mid-70% range. United Microelectronics reiterated its <a target="_blank" href="https://www.benzinga.com/news/earnings/25/04/44948817/united-microelectronics-boasts-q1-gains-faces-caution-over-tariff-impact-on-future-orders" rel="noreferrer noopener">capital expenditure</a> target of $1.8 billion for 2025.
Price Action: UMC stock is trading lower by 4.21% to $6.82 premarket at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46666398/taiwan-semiconductor-stock-slips-as-samsung-scores-16-5-billion-tesla-chip-deal" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor Stock Slips As Samsung Scores $16.5 Billion Tesla Chip Deal</a></li>
</ul>
Photo by Dr David Sing via Shutterstock

Asia

Movers

Tech

United Microelectronics Chief Cautions Currency, Trade Policy Could Dampen Gains

VFC: 40% &#x7C; <a href="https://www.benzinga.com/node/46715376">VF Corp shares are trading higher after the company reported better-than-expected Q1 EPS and sales.</a>
&nbsp;
MRVL: 9% &#x7C; <a href="https://www.benzinga.com/node/46715461">Marvell Technology shares are trading higher. The company announced a collaboration with Rebellions to offer high-performance, energy-efficient AI systems tailored for regionally driven and sovereign-backed AI initiatives across APAC and the Middle East.</a>
&nbsp;
FGF: 60% &#x7C; <a href="https://www.benzinga.com/node/46714167">Fundamental Global Raises $200M In Private Placement To Launch Ethereum Treasury Strategy On ETH's 10th Anniversary</a>

Trading Ideas

MRVL

Market-Moving News for July 30th

INTU reverses early weakness after the alert and climbs 1.3%
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/29205035/Screenshot-2025-07-29-at-4.47.10%E2%80%AFPM-880x1024.png" alt="" class="wp-image-16621" /></figure>
Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) experienced a Power Inflow today, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:19 AM on July 29th, a significant trading signal occurred for Intuit Inc. (INTU) as it demonstrated a Power Inflow at a price of $797.47 This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Intuit's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Intuit's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for INTU,<a href="https://benzinga.grsm.io/register174"> Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_July2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_July2025</a>
which are responsible for parts of the data within this article.
After Market Close UPDATE:
The price at the time of the Power Inflow was $797.47. The returns on the High price ($807.93) and Close price ($806.34) after the Power Inflow are respectively 1.3% and 1.1%.
Past performance is not indicative of future results

Equities

Technicals

Opinion

Signals

INTU

Intuit Stock Rises 1.3% After Key Trading Signal

REZI

Resideo To Pay $1.59B To Honeywell In Q3 2025, Eliminating All Future Obligations Under Indemnification Deal Signed In 2018

Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), a global leader in digital payments, today announced a major advancement for Fleet Operators. With the addition of Google Pay tokenization and push-to-wallet, Visa addresses the long-standing challenge of fleet data tags being tied solely to the plastic card chip. Now, fleet data tags can be configured by the issuer, fintech or processor, allowing custom data tags to be dynamically provisioned during the tokenization process. Once loaded into Google Pay with these fleet data tags, Visa's contactless specification helps ensure that token payment data and fleet data tags are transmitted to the point of sale (POS) and actioned upon seamlessly.

GOOGL

Visa Adds Google Pay Support for Fleet Cards, Making Contactless Fuel Payments Smarter and Easier

General

QBTS

D-Wave Quantum Announces  Initiative Focused On Cryogenic Packaging

Resideo Announces Plan To Spin Off ADI Business In Tax-Free Transaction, Creating Two Independent Public Companies By H2 2026

<a href="https://www.globenewswire.com/Tracker?data=YKczEcajITWbaIoAk2pB99mUeLgyr30Rgc8fsmTLQYMYhjvgfRG_9CUsQygs9HAyJlFlZTRlCvf_Y9ztkAISj1aEI9SbROaxLd78BwrNsERY-5hEXP8PdrJUNDcSuesClXyfFFS1jT40kO3jL3g8Uwn_slsfe0OImbvrtR9qbe1XcvUYX0KcYXS1HxUDEtyEWhn_ptcJM62EAY1mdv8rQJXufEiYLCerFXUURcVz-faji-gZi5lN9r_utwFKkhn5zbwfbrx2UI56yLbGDmqnZC2EgY5qPIMqM-TysecC2V8HlRXRO3RiHCUDAStc5Q3-LJOQmRBmuEol2m-IXf8XvAI770bgCPvJI82odagRfrvJj7ORHgwwmk6SDQ0j1jMOQXtBPdsmlkFkpkgH-oMxnQ==">Sight Sciences</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGHT#NASDAQ">SGHT</a>) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced the results of a cost-utility analysis (CUA) assessing the cost-effectiveness of the TearCare&#xAE; System compared to cyclosporine 0.05% (CsA) for the treatment of moderate to severe meibomian gland disease (MGD) associated dry eye disease (DED). The analysis, published ahead of print in Expert Review of Pharmacoeconomics and Outcomes Research, demonstrated that TearCare is not only associated with greater health utility over time but also resulted in significant cost savings compared to CsA, offering a more efficient and patient-centric approach to treating this common ocular disease.
The analysis, conducted from a US healthcare payer perspective using a 1-year time horizon, revealed that TearCare resulted in lower per-patient annual costs ($4,916) and higher quality-adjusted life years (QALYs; 0.76) compared to CsA ($5,819 and 0.74 QALYs, respectively). This translated to per-patient annual cost savings of $903 and an incremental benefit of 0.014 QALYs.
"This cost-utility analysis confirms what many of us in clinical practice have observed," said Nathan Lighthizer, OD, FAAO, lead investigator of the study and Professor and Dean for the NSU Oklahoma College of Optometry. "TearCare not only improves patient outcomes but also represents a more economically sustainable approach to managing MGD-associated dry eye disease. The demonstrated cost savings of over $900 per patient per year are significant in our current healthcare environment."
Key Findings:
<ul>
<li>Assuming two procedures over a 1-year time horizon, TearCare demonstrated a cost-saving advantage over CsA, reducing per-patient costs by $903 annually.</li>
<li>Patients receiving TearCare experienced an incremental QALY gain of 0.014, compared to those on CsA.</li>
<li>Scenario analyses confirmed the robustness of the results, showing that even when adjusting assumptions—such as the proportion of patients improving to a milder disease state—TearCare consistently delivered cost savings and greater QALY gains over CsA.</li>
</ul>

SGHT

Sight Sciences Study Finds TearCare More Effective and Cheaper Than Cyclosporine for Dry Eye Relief

Health Care

Press Releases

Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta

NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

NextCure Announces Acceptance of IND Application for LNCB74

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

Comments

NextCure

Intérêt court

NextCure (NASDAQ:NXTC) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL